Early symptom-associated inflammatory responses shift to type 2 responses in controlled human schistosome infection.
Emma L HoulderKoen Alexander StamJan Pieter R KoopmanMarion H KönigMarijke C C LangenbergMarie-Astrid HoogerwerfPaula NiewoldFriederike SonnetJacqueline J JanseMiriam Casacuberta PartalJeroen C SijtsmaLaura H M de Bes-RoeleveldYvonne C M KruizeMaria M YazdanbakhshMeta RoestenbergPublished in: Science immunology (2024)
Schistosomiasis is an infection caused by contact with Schistosoma -contaminated water and affects more than 230 million people worldwide with varying morbidity. The roles of T helper 2 (T H 2) cells and regulatory immune responses in chronic infection are well documented, but less is known about human immune responses during acute infection. Here, we comprehensively map immune responses during controlled human Schistosoma mansoni infection using male or female cercariae. Immune responses to male or female parasite single-sex infection were comparable. An early T H 1-biased inflammatory response was observed at week 4 after infection, which was particularly apparent in individuals experiencing symptoms of acute schistosomiasis. By week 8 after infection, inflammatory responses were followed by an expansion of T H 2 and regulatory cell subsets. This study demonstrates the shift from T H 1 to both T H 2 and regulatory responses, typical of chronic schistosomiasis, in the absence of egg production and provides immunological insight into the clinical manifestations of acute schistosomiasis.
Keyphrases
- immune response
- endothelial cells
- inflammatory response
- dendritic cells
- transcription factor
- clinical trial
- toll like receptor
- cell proliferation
- magnetic resonance imaging
- intensive care unit
- heavy metals
- cell death
- single cell
- depressive symptoms
- computed tomography
- signaling pathway
- physical activity
- risk assessment
- drinking water
- pluripotent stem cells
- study protocol
- lps induced
- cell cycle arrest
- toxoplasma gondii
- endoplasmic reticulum stress
- placebo controlled